ClinicalTrials.gg
TerminatedNCT05149807Updated Aug 20, 2025

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

A Phase 2/3 interventional study of SHR-1701 injection and Placebo in Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Terminated at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
R\&d strategy adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 5 under way, 2 of them phase 3. Stomach Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
9th of 14
81 · median 151
Started
2022
the only one that year
Phase 2/3
Only one
of the 14
Registered
10th of 14
by date

Among the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by enrollment, is the only one that started in 2022, is the only one in phase 2/3, and was the 10th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

5 of the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a multi-center phase II/III clinical study consisting of two stages: Stage I is a single-arm open-label phase II study to preliminarily explore the efficacy and safety of SHR-1701 plus S-1 and oxaliplatin mainly by the endpoint of pCR rate.

Stage II is a randomized, double-blind, multi-center phase III study of SHR-1701 plus S-1 and oxaliplatin versus placebo plus S-1 and oxaliplatin as perioperative treatment in subjects with resectable GC or GEJC. A total of 846 treatment naïve subjects will be enrolled, and primary endpoint of this stage is Independent Review Committee (IRC)-assessed EFS.

03

Conditions studied

  • Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed with GC or GEJC, histologically confirmed to be adenocarcinoma, and have no previous anti-tumor treatments for GC or GEJC.
  2. Aged 18 or above, male or female.
  3. Be suitable for (investigator's assessment) and planning to undergo therapy + radical surgery with curative intent before entering into the study.
  4. locally advanced Gastric Cancer or Gastroesophageal Junction Cancer confirmed by investigator.
  5. Be able to provide tumor tissue blocks.
  6. (ECOG) performance status score of 0-1.
  7. of ≥ 6 months.
  8. Have adequate organ and bone marrow functions.
  9. Women without refer to women, or women who underwent bilateral oophorectomy with medical records. Male subjects and female subjects of childbearing potential must agree to take a medically approved measure (refer to Appendix 4) during the study, within 3 months after the last dose of product (SHR-1701), and within 9 months after the last dose of chemotherapy agents (S-1 and oxaliplatin); have a negative serum pregnancy test result within 3 days prior to the start of study treatment and not be breastfeeding.
  10. Subjects must agree and have signed the form, be willing and able to follow the scheduled visits, study treatment, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Have known squamous cell carcinoma, undifferentiated carcinoma, or other histological types of gastric cancer, or adenocarcinoma mixed with gastric cancer of other histological types.
  2. Have unresectable factors, including unresectable tumors or to surgery or refusal of surgery.
  3. Have more than 20% weight loss within 2 months prior to enrollment or randomization.
  4. Have previously received some treatments or medications including anti-tumor treatments.
  5. Diagnosed with other malignant tumors within 5 years prior to enrollment.
  6. Have any active, known, or suspected disease.
  7. Have bleeding symptoms or clear bleeding tendency within 3 months prior to enrollment or randomization; have gastrointestinal perforation and/or gastrointestinal fistula within 6 months prior to enrollment or randomization; have arterial/venous thrombotic events within 6 months prior to enrollment or randomization.
  8. Have major vascular disease within 6 months prior to enrollment or randomization.
  9. Have severe, unhealed, or dehisced wounds and active ulcers or untreated fractures.
  10. Have intestinal obstruction and/or clinical signs or symptoms of gastrointestinal obstruction within 6 months prior to enrollment or randomization.
  11. Have interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic disease.
  12. Have known allergies to the study drug or their ; have severe allergic reactions to other monoclonal antibodies.
  13. Have infection or known AIDS, active untreated hepatitis or co-infection with and C.
  14. Have uncontrolled cardiac symptoms or disease:
  15. Have received systemic antibiotics for ≥ 7 days within 4 weeks prior to enrollment or randomization, or have unexplained fever > 38.5 °C during screening or before the first dose.
  16. Have known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  17. Have been screened for other clinical studies but failed the screening because expression did not meet the inclusion criteria or met the exclusion criteria; have participated in clinical studies of any other drugs, less than 4 weeks or 5 half-lives of the drug between the last dose of these study treatments and enrollment/randomization for this study (whichever is longer).
  18. Have a known history of psychotropic substance abuse or drug abuse.
  19. Have other severe physical or psychiatric disorders or laboratory abnormalities, which may increase the risk of participation in this study or interfere with the study results, or deemed unsuitable by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    SHR-1701 + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin

    Drug: SHR-1701 injection

  • Placebo comparator
    Placebo + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin

    Drug: Placebo

Interventions

  • SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin

  • DrugPlacebo

    Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin

06

What researchers measure

Primary outcomes

  1. Phase II : Pathological Complete Response pCR rate.

    pCR rate is defined as the proportion of subjects whose specimens (including primary lesion and lymph nodes) obtained during GC or GEJC radical surgery are pathologically assessed to be free of residual live tumor cells after neoadjuvant therapy.

    Time frame: Up to approximately 23 months

  2. Phase III : Event-free Survival (EFS)

    EFS is defined as time from randomization to PD or death (whichever occurs first), detailed that tumor progression/recurrence or new lesion confirmed by RECIST v1.1 criteria or death due to any cause.

    Time frame: Up to approximately 57 months

Secondary outcomes

  1. Disease-free Survival (DFS).

    DFS is defined as time from R0 resection to PD or death (whichever occurs first), detailed that tumor recurrence or new lesion confirmed by RECIST v1.1 criteria or death due to any cause.

    Time frame: Up to approximately 57 months

  2. Preoperative Objective Response Rate (ORR).

    Preoperative ORR is defined as proportion of enrolled or randomized subjects with a best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1 criteria during neoadjuvant therapy period.

    Time frame: Up to approximately 57 months

  3. Major pathological response (MPR) rates.

    MPR rate is defined as proportion of subjects whose primary lesion specimens obtained during GC or GEJC radical surgery are pathologically assessed to have \< 10% residual live tumor cells relative to the primary tumor tissue (Becker grade 1a or 1b) after neoadjuvant therapy.

    Time frame: Up to approximately 23 months

  4. R0 resection rate

    R0 resection rate is defined as proportion of subjects without gross or microscopic residual tumor (negative margin) after neoadjuvant therapy and GC or GEJC radical surgery.

    Time frame: Up to approximately 23 months

  5. Overall Survival (OS).

    OS is defined as time from randomization to death of any cause.

    Time frame: Up to approximately 57 months

  6. Percentage of Participants Who Experience One or More Adverse Events (AEs).

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The percentage of participants who experience at least one AE will be presented.

    Time frame: Up to approximately 57 months

  7. 30-day postoperative mortality.

    30-day postoperative mortality is defined as proportion of subjects who died due to any reason within 30 days after radical surgery for GC.

    Time frame: Up to approximately 24 months

07

Study locations

20 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • The Second Affiliated Hospital Of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350000, China
  • Southern Medical University NanFang Hospital
    Guangzhou, Guangdong 510000, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510000, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Xingtai People's Hospital
    Xingtai, Hebei 054031, China
  • Anyang Cancer Hospital
    Anyang, Henan 455000, China
  • The First Affiliated Hospital of Henan University of Science & Technology
    Luoyang, Henan 471003, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Subei people's Hospital of Jiangsu Province
    Yangzhou, Jiangsu 225001, China
  • Liaoning Cancer Hospital&Institute
    Shenyang, Liaoning 110801, China
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200000, China
  • The Second Affiliated Hospital of Air Force Military University Tangdu Hospital
    Xi’an, Shanxi 7100038, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi 710061, China
  • Sichuan Cancer Hospital & Institute
    Chengdu, Sichuan 610042, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Apr 2024, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2021
First posted
Dec 8, 2021
StartActual
Jan 26, 2022
Primary completionActual
Apr 3, 2024
CompletionActual
Apr 3, 2024
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05149807
Responsible party
Sponsor
First posted
Dec 8, 2021
Start date
Jan 26, 2022
Primary completion
Apr 3, 2024
Completion
Apr 3, 2024
Last update
Aug 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1701

Start the discussion